U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H26O11
Molecular Weight 466.4352
Optical Activity UNSPECIFIED
Defined Stereocenters 9 / 9
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of AGNUSIDE

SMILES

[H][C@@]12C=CO[C@@H](O[C@]3([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@]1([H])C(COC(=O)C4=CC=C(O)C=C4)=C[C@H]2O

InChI

InChIKey=GLACGTLACKLUJX-QNAXTHAFSA-N
InChI=1S/C22H26O11/c23-8-15-17(26)18(27)19(28)22(32-15)33-21-16-11(7-14(25)13(16)5-6-30-21)9-31-20(29)10-1-3-12(24)4-2-10/h1-7,13-19,21-28H,8-9H2/t13-,14+,15+,16+,17+,18-,19+,21-,22-/m0/s1

HIDE SMILES / InChI

Description

Agnuside (AGN), an iridoid glycoside, is the principle active phytoconstituent and a chemotaxonomic marker of the genus Vitex. It is isolated from V. agnus castus, V. negundo, and V. cymosa and composed of aucubin and p-hydroxy benzoic acid (PHBA). Agnuside has exhibited estrogen-like activity which might be the reason for its use in premenstrual syndrome problems in women of fertile age as well as in menopause. It has also been reported to possess anti-arthritic activity in the polyarthritis rats which was associated with significant suppression of the inflammatory mediators and T-cell mediated cytokinines. Recently, Agnuside has shown higher hepatoprotective potential in rats in comparison to silymarin, a commercially available herbal hepatoprotective agent. In addition, Agnuside has shown an inhibitory effect on P-glycoprotein (P-gp) ATPase activity. The diversified therapeutic indications of AGN with a profoundly high medicinal value have created great curiosity among researchers for its further investigation as a medicinal agent.

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

PubMed

Sample Use Guides

In Vivo Use Guide
Mice: one group received the intravenous (i.v.) dose (5.3 mg/kg body weight) through caudal vein (0.2 mL) and the second group received an oral dose (53 mg/kg body weight) suspended in 0.5% w/v sodium carboxymethyl cellulose by oral gavage.
Route of Administration: Other
In Vitro Use Guide
Agnuside could stimulate the proliferation of MCF-7 cells dose dependently (range from 100 nM to 10 microM)